Company Background

US-based Dendritic Nanotechnologies Inc (DNT) a subsidiary of Starpharma Holdings, holds rights to a large body of dendrimer and dendritic polymer related IP. Dendritic NanoTechnologies is commercialising this IP across the fields of gene transfection, MRI contrast agents, drug delivery and a range of electronic applications. Research is continuing in collaboration with the Central Michigan University.

In 2003 DNT was selected as an industrial partner in the US Army’s Institute for Soldier Nanotechnologies at MIT, and in January 2005 it signed a deal with Dow Chemical, transferring Dow’s portfolio of 196 patents in the field of dendrimers in exchange for equity in DNT. Australian biotechnology firm, Starpharma is a major shareholder in DNT.